fortune 昨天的文章。，请看一下

“The fundamentals of our story are in place, which is this is the first drug—to our knowledge—that can restore cognition,” Cassava’s founder and chief executive Remi Barbier said in an interview. 。

Despite a stock rally that makes his 5% stake—including options—worth more than $100 million, Barbier says he’s not selling. “I know the science, I know the data, I know the disease and this stuff looks promising and I’m putting my money where my mouth is.”

所有跟帖： 

• biogen被调查不应该对SAVA不利。这叫做overreact ，MM。。。 -雨夫子- ♂ (0 bytes) () 07/10/2021 postreply 08:07:30

• 谢谢夫子，下星期再接回来！what about anvs? -Lalala2120- ♂ (0 bytes) () 07/10/2021 postreply 08:20:32

• ANVS 上周5.@85.，这周5 到105，没有一直涨的股票，逢低买入，逢低。。 -雨夫子- ♂ (0 bytes) () 07/10/2021 postreply 08:26:53

• 好滴，逢低逐步加仓！听您的没错！ -Lalala2120- ♂ (0 bytes) () 07/10/2021 postreply 08:31:53

• 有什么临床CRO股推荐吗？谢谢！ -gl00ad2- ♂ (0 bytes) () 07/10/2021 postreply 08:40:51

• 点赞夫子大侠！ -qjwt- ♂ (0 bytes) () 07/10/2021 postreply 09:47:20

• Great。news medium Stat make looks like FDA investigate SAVA‘s dr -雨夫子- ♂ (0 bytes) () 07/10/2021 postreply 10:16:40

• not biogen’s drug，哈哈，this cause panic selling 。昨天 -雨夫子- ♂ (0 bytes) () 07/10/2021 postreply 10:17:56